Medicine
SymlinPen 2700 mcg/2.7 mL injection
SymlinPen 2700 mcg/2.7 mL injection is a prescription medicine containing Pramlintide for subcutaneous use, marketed by AstraZeneca Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Storage Conditions Dosage Form Unopened (not in use) Refrigerated Open (in…
Key facts
- Active ingredient (INN)
- Pramlintide
- Brand
- SymlinPen
- Strength
- 2700 mcg/2.7 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 2 cartridges of 2.7 mL
- Marketing authorisation holder
- AstraZeneca Pharmaceuticals
- Manufacturer
- AstraZeneca Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Storage Conditions Dosage Form Unopened (not in use) Refrigerated Open (in use) Refrigerated or Temperature up to 86°F (30°C) 1.5 mL pen-injector Until Expiration Date Use Within 30 Days 2.7 mL pen-injector Storage conditions are summarized in Table 9.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BX05 Pramlintide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 January 2015
- Identifiers
- RxCUI 861042, 861043, 861044 +1DailyMed set ID 4aea30ff-eb0d-45c1-b114-3127966328ffNDC 0310-6627Application NDA021332
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 cartridge in 1 carton / 2.7 mL in 1 cartridge | 0310-6627-02 | AstraZeneca Pharmaceuticals | 8 January 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 16 March 2005 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pramlintide
Clinical summary
Pramlintide is an amylin analog indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. MedsAcross supplies Pramlintide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PramlintideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SymlinPen prescribing information (AstraZeneca Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need SymlinPen 2700 mcg/2.7 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.